These B7 gene-modified LEXs could efficiently promote CD4+ T cell proliferation, stimulate Type I cytokine secretion, and induce an antigen-specific anti-leukemia cytotoxic T lymphocyte (CTL) response, leading to a stronger anti-leukemia protective immunity in vivo. The gene discussed is CD80; the disease is leukemia.